Evaluate the Safety and Efficacy of Reslizumab for Patients With Eosinophilic Asthma

Study Title
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
Teva Identifier
C38072/3085 | 2010-024540-15
ClinicalTrials.gov Identifier
NCT01290887
Study Status
Terminated
Trial Condition(s)
Eosinophilic Asthma
Interventions
Drug: Reslizumab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
12 Years to 75 Years
Trial Duration
06/01/2011 - 01/01/2015
Phase
Phase 3

Study Type

Interventional